These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 34059997)

  • 1. Narrative review of the relationship between COVID-19 and PJP: does it represent coinfection or colonization?
    Chong WH; Saha BK; Chopra A
    Infection; 2021 Dec; 49(6):1079-1090. PubMed ID: 34059997
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Gentile I; Viceconte G; Lanzardo A; Zotta I; Zappulo E; Pinchera B; Scotto R; Schiano Moriello N; Foggia M; Giaccone A; Messina G; Salvatore P; Buonomo AR; Federico Ii Covid-Team
    Int J Environ Res Public Health; 2021 Oct; 18(21):. PubMed ID: 34769913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High initial (1, 3) Beta-d-Glucan concentration may be a predictor of satisfactory response of c aspofungin combined with TMP/SMZ for HIV-negative patients with moderate to severe Pneumocystis jirovecii pneumonia.
    Jin F; Liu XH; Chen WC; Fan ZL; Wang HL
    Int J Infect Dis; 2019 Nov; 88():141-148. PubMed ID: 31442630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pneumocystis jirovecii Pneumonia in the Non-HIV-Infected Population.
    Avino LJ; Naylor SM; Roecker AM
    Ann Pharmacother; 2016 Aug; 50(8):673-9. PubMed ID: 27242349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Negative serum (1,3) -β-D-glucan has a low power to exclude Pneumocystis jirovecii pneumonia (PJP) in HIV-uninfected patients with positive qPCR.
    Huang Y; Yi J; Song JJ; Du LJ; Li XM; Cheng LL; Yan SX; Li HL; Liu YM; Zhan HT; Dou YL; Li YZ
    Ann Clin Microbiol Antimicrob; 2023 Nov; 22(1):102. PubMed ID: 37986091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent Infection with SARS-CoV-2 and
    Gioia F; Albasata H; Hosseini-Moghaddam SM
    J Fungi (Basel); 2022 May; 8(6):. PubMed ID: 35736068
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Viceconte G; Buonomo AR; Lanzardo A; Pinchera B; Zappulo E; Scotto R; Schiano Moriello N; Vargas M; Iacovazzo C; Servillo G; Gentile I;
    Infect Dis (Lond); 2021 May; 53(5):382-385. PubMed ID: 33645461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High incidence of Pneumocystis jirovecii pneumonia in allogeneic hematopoietic cell transplant recipients in the modern era.
    Evernden C; Dowhan M; Dabas R; Chaudhry A; Kalra A; Dharmani-Khan P; Gregson D; Johnson A; Jupp J; Jimenez-Zepeda V; Jamani K; Duggan P; Tay J; Khan F; Daly A; Storek J
    Cytotherapy; 2020 Jan; 22(1):27-34. PubMed ID: 31889628
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Takahashi T; Saito A; Kuronuma K; Nishikiori H; Chiba H
    Medicina (Kaunas); 2022 Aug; 58(9):. PubMed ID: 36143828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL.
    Atkinson A; Miro JM; Mocroft A; Reiss P; Kirk O; Morlat P; Ghosn J; Stephan C; Mussini C; Antoniadou A; Doerholt K; Girardi E; De Wit S; Kraus D; Zwahlen M; Furrer H;
    J Int AIDS Soc; 2021 Jun; 24(6):e25726. PubMed ID: 34118121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylaxis for Pneumocystis jirovecii pneumonia in patients with inflammatory bowel disease: A systematic review.
    Sierra CM; Daiya KC
    Pharmacotherapy; 2022 Nov; 42(11):858-867. PubMed ID: 36222368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-center retrospective analysis of Pneumocystis jirovecii pneumonia in patients after deceased donor renal transplantation.
    Zou J; Wang T; Qiu T; Zhou J; Chen Z; Ma X; Jin Z; Xu Y; Zhang L
    Transpl Immunol; 2022 Jun; 72():101593. PubMed ID: 35367619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time to trimethoprim/sulfamethoxazole initiation among patients with rheumatic disease complicated by Pneumocystis jirovecii pneumonia: impact on 90-day mortality.
    Song S; Zhang Y; Yu J; Xie C; Chen Y; Zhang X
    BMC Infect Dis; 2022 Dec; 22(1):961. PubMed ID: 36575406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors associated with Pneumocystis jirovecii pneumonia in non-HIV immunocompromised patients and co-pathogens analysis by metagenomic next-generation sequencing.
    Huang L; Xu S; Huang Z; Chen Y; Xu N; Xie B
    BMC Pulm Med; 2023 Feb; 23(1):72. PubMed ID: 36829171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VV-ECMO combined with prone position ventilation in the treatment of Pneumocystis jirovecii pneumonia: A case report.
    Jia L; Zhang Z; Bai Y; Du Q
    Medicine (Baltimore); 2022 Jan; 101(1):e28482. PubMed ID: 35029898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumocystis jirovecii pneumonia in AIDS and non-AIDS immunocompromised patients - an update.
    Lee YT; Chuang ML
    J Infect Dev Ctries; 2018 Oct; 12(10):824-834. PubMed ID: 32004150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discontinuing Pneumocystis jirovecii Pneumonia Prophylaxis in HIV-Infected Patients With a CD4 Cell Count <200 cells/mm3.
    Sidhu VK; Foisy MM; Hughes CA
    Ann Pharmacother; 2015 Dec; 49(12):1343-8. PubMed ID: 26358129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pneumocystis jirovecii pneumonia in children. A retrospective study in a single center over three decades.
    García-Moreno J; Melendo-Pérez S; Martín-Gómez MT; Frick MA; Balcells-Ramírez J; Pujol-Jover M; Martín-Nalda A; Mendoza-Palomar N; Soler-Palacín P
    Enferm Infecc Microbiol Clin (Engl Ed); 2020 Mar; 38(3):111-118. PubMed ID: 31272810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics and risk factors of in-hospital mortality in patients coinfected with Pneumocystis jirovecii and Aspergillus.
    Zhong Y; Ji T; Qin D; Cheng D
    J Mycol Med; 2023 Mar; 33(1):101330. PubMed ID: 36265259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus-negative immunocompromised patients: A systematic review.
    Messiaen PE; Cuyx S; Dejagere T; van der Hilst JC
    Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28035717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.